TRPV4 and neuropathy: Importantly, acute application of GSK219 rapidly suppressed SNI-induced enhancement of both electrical and synaptic activities, suggesting that TRPV4 channels are likely constitutively active during SNI-induced neuropathy and might serve as a promising drug target for treating chronic neuropathic pain.